C - Reactive Protein, Coronary Heart Disease and Ischemic Stroke in the Elderly: The Cardiovascular Health Study by Li, Xia
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2006
C - Reactive Protein, Coronary Heart Disease and
Ischemic Stroke in the Elderly: The Cardiovascular
Health Study
Xia Li
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Epidemiology Commons
© The Author
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/1377
C - REACTIVE PROTEIN, CORONARY HEART 
DISEASE AND ISCHEMIC STROKE IN THE ELDERLY 
THE CARDIOVASCULAR HEALTH STUDY 
Xia Li 
Tilahun Adera, MPH, PhD 
Jeanenne J. Nelson, PhD 
Department of Epidemiology and Community Health 
Master of Public Health Program 
MPH Research Project: EPlD 691 
Virginia Commonwealth University 
Richmond, Virginia 
April 2006 
DEDICATION 
I would like to dedicate this work to old women and men who suffered from cardiovascular 
diseases. Reflecting on the powerful motivation for health promotion a common disease can 
foster. It is my hope that the research presented herein will contribute to a reduction in 
membership. 
TABLE OF CONTENTS 
Acknowledgements ..................................................................................... 1 
Abstract .................................................................................................... 2 
Introduction ............................................................................................. 3 . 7 
. Methods ............................................................................................... 8 I I 
Results ................................................................................................ 12 . 19 
. Discussions .......................................................................................... 20 27 
Conclusions .............................................................................................. 28 
References .......................................................................................... 29 . 33 
Tables 1-19 .......................................................................................... 34 . 50 
Figures 1-2 ............................................................................................... 51 
Appendix A: SAS Syntax ..................................................................... 52 . 137 
Appendix B: SAS output .................................................................... 138 . 155 
ACKNOWLEDGEMENTS 
I am very grateful for the unique opportunity of working closely with such excellent experts as 
Drs. Tilahun Adera, Jeanenne J. Nelson, and Ms. Bobbie L. Coleman on this research project and 
sharing the challenge and rewards in the process. Certainly the work of my graduate advisor, Dr. 
Adera, and preceptors, Dr. Nelson and Ms. Coleman, deserve every opportunity for 
acknowledgement. As my advisor, I continually appreciate Dr. Adera for his support, 
encouragement, and flexibility. Additionally, a number of others have contributed. Ms. Lisa S. 
Anderson provided a lot of help and supports for my study here and this research project. 
Dr. Chunlin Wang's suggestions on the data analyses using SAS provided a critical spark, such 
as how to select potential confounders for adjustment using SAS, and checked some pieces of 
SAS codes related to the interaction of CRP with sex or race on the incidence of CHD or 
ischemic stroke. Dr. Elizabeth E. Turf, a director of the MPH research project, gave great 
comments on this project. Without Dr. Edward L. Murrelle's help, I have never successfully did 
the research internship at GSK last summer, and smoothly started this project. 
Finally, I am humbled by the graciousness of my family and friends, particularly my mother, 
Zhenhua Guo, and boyfriend, Siming. My great mom has provided continued emotional support 
throughout completion of this project and study here. Siming, a researcher in astronomy, helped 
me keep perspective. Each time what happened depresses me, he often asks, "How do you 
successfully conduct a research if you get the grant of one million dollars?" 
C - Reactive Protein, Coronary Heart Disease and Ischemic Stroke 
in the Elderly: The Cardiovascular Health Study 
Xia Li 
Advisor: Dr. Tilahun Adera 
Preceptor: Dr. Jeanenne J. Nelson 
Background-C-reactive protein (CRP) has been associated with increased risk of coronary heart 
disease (CHD) and stroke, but much of the research had focused on middle-aged populations with, 
limited prospective, population-based, longitudinal data. In this study, we examined data from an 
elderly population and described the distribution of CRP concentrations and the prevalence of 
elevated CRP levels (>3 mgll), examined the association between CRP levels and incidence of CHD 
or ischemic stroke, and assessed the potential interaction of CRP with sex or race on the incidence 
of CHD or ischemic stroke. 
Methods- Baseline CRP levels were measured in a cohort of 57 13 participants 265 years of age 
from the Cardiovascular Health Study (CHS) using a high-sensitivity assay. The cohort included 
3859 (68%) subjects free of cardiovascular disease and 1 104 (1 9%) with existing CVD. Data were 
collected from 1989- 1990 or 1992- 1993 to June 30, 1997. SAS 9.10 software was used for analyses 
and statistical tests included t test, ANOVA, xZ, Kaplan-Meier method, Log-rank test, and Cox 
proportional hazards regression. 
Results-CRP distribution was highly skewed toward higher values, thus necessitating the use of 
the median and log transformation of the mean. For all participants, the median of CRP 
concentrations was 1.92 mgll; the geometric mean was1.97 mgll. Thirty percent of participants had 
CRP values >3 mgll. Among subjects with prevalent CHD and those free of CHD at baseline the 
median CRP levels were 2.32 mgll and 1.75 mgll, respectively. The prevalence of elevated CRP 
levels was 36% in participants with baseline CHD and 26% in those free of CHD; it was higher in 
women than in men (32% vs. 27%, respectively), in blacks than in whites (42% vs. 28%, 
respectively), in subjects taking versus not taking cardiovascular medicines (35% vs. 22%, 
respectively). The mean CRP were similar among participants with and without initial statin uses (P 
= 0.3 155). For CHD participants, 37% of statin users and 36% of nonusers had elevated CRP levels. 
During 8 years of follow-up, 270 incident CHD events and 245 incident ischemic strokes occurred. 
Incidence rate of CHD and ischemic stroke was 10.7 and 9.7 per 1000 person-years, respectively. 
The relative risk (RR) of CHD and ischemic stroke for CRP >3 mgll compared with <1 mgll was 
1.48 (95%CI, 1 .01- 2.18) and 1.58 (95%CI, 1.10-2.29), respectively, with adjustment for traditional 
CV risk factors. The population-attributable risk of CHD and ischemic stroke associated with 
elevated CRP levels was 11% and 13%, respectively. There was no effect modification by sex and 
race in the association of CRP with CHD (P for sex-CRP interaction, 0.7638; P for race-CRP 
interaction, 0.4428). Similarly, no effect modification was observed by sex and race in the 
association of CRP with ischemic stroke (P for sex-CRP interaction, 0.1721 ; P for race-CRP 
interaction, 0.5486). 
Conclusions- CRP levels were higher among prevalent CHD subjects than among those without 
CHD. Women, blacks, and CV drug users had elevated CRP levels. Elevated CRP was associated 
with increased 8-year risk of CHD and ischemic stroke. Neither sex nor race modified the 
association between CRP and CHD or ischemic stroke. Future studies will be needed to explore new 
CRP thresholds for the elderly, and to examine if reduction of CRP levels using pharmacological 
agents reduces the risk of CHD or stroke. 
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INTRODUCTION 
Approximately 1,200,000 coronary heart disease events and more than 700 000 strokes occur in 
the United States each year, with 58% of CHD and 71% of strokes occurring among people aged 
65 and older, of which 88% of all strokes are ischemic.' The estimated direct and indirect cost 
of CVD for 2006 is $403.1 billion, including $142.5 billion for CHD and $57.9 billion for stroke. 
Although traditional risk factors account for much of the risk for CHD events, and at least 1 
risk factor precedes 87% to 100% of CHD deaths, not all CHD risk is explained by the combined 
effect of traditional risk  factor^.^ For example, one half of all myocardial infarctions and stroke 
occur in adults with normal serum cholesterol  level^.^ So it is paramount to identify new risk 
markers for CVD and improve identification of older population at high risk. 
C-reactive protein (CRP), a biomarker of low-grade systemic inflammation, has been reported as 
a novel risk marker for myocardial infarction (MI), stroke, and sudden cardiac death 
in a series of prospective epidemiologic studies of apparently healthy adults. Recent clinical 
practice recommendations from the CDCIAHA support the use of CRP testing in primary 
prevention, suggesting that CRP values < 1 mgll indicate normal levels, concentrations of 1 to 3 
mgll indicate intermediate risk, and levels > 3 mgll indicate increased risk.'' 
An endogenous biochemical, CRP, originally named by Tiller and Francis in 1930," is 
synthesized in the liver, but vascular sources, including cells in atheromas, also produce CRP. l 2  
l 3  l4  I' CRP belongs to the pentraxin family of proteins.'5 This protein is very sensitive to 
inflammation, and its concentration can increase rapidly in response to a wide range of stimuli. 
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For example, interleukin-6 and other cytokines stimulate the release of CRP, increasing its level 
by 500-fold or more during an acute inflammatory response to tissue injury or infection. l6  l 7  In 
the past decade, a role for inflammation has become well established in theories describing the 
atherosclerotic disease process.'8 l 9  For a pathological viewpoint, infections and inflammation 
(which play a major role in determining atherosclerotic plaque vulnerability) may promote 
atherosclerosis and thrombosis by elevating serum levels of fibrinogenY2O leukocytes, 21 clotting 
factors,22 and ~ y t o k i n e s ~ ~  and by altering the metabolism and functions of endothelial cells and 
monocyte m a ~ r o ~ h a ~ e s . ~ ~  Low-grade infections, reflected in elevated levels of various acute- 
phase proteins,25 may be partly responsible for the inflammatory processes observed in 
atherosclerotic lesions, which in turn may relate to the occurrence of CVD. (Figure 1) 
Specifically, CRP induces complement and upregulates the expression of cellular adhesion 
molecules. 26 High concentrations of CRP mediate LDL uptake by endothelial macrophages and 
induce the recruitment of monocytes into the walls of blood vessels.I2 These effects contribute 
to and may even accelerate the formation of fatty streaks in early atherosclerosis. 
Although most of recent studies of CRP and CVD incidence have been prospective, they have 
often used nested case-control designs, which do not fully provide data on the CRP distribution 
in the entire study population. Furthermore, matching of cases and controls limits comparisons 
across sex and age. Most studies to date also have been carried out in groups of people of 
European ancestry, and there are few data on African Americans in particular. The use of 
different assays across studies also makes it difficult to define cutpoints. This study used high- 
sensitivity methods that are capable of reliably measuring CRP concentrations 10.15 mg/L 
(approximately the first and second percentiles of CRP distribution in healthy adults). 27 28 AS a 
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recent report suggested, lo  critically needed is a firm understanding of the distribution of CRP in 
such an important population subgroup as the elderly, especially the distribution of high-risk 
levels of CRP in this age subgroups. 
Current recommendations for CRP testing suggest uniform CRP thresholds to characterize the 
relative risk of CV events based on approximate tertile values in several populations.29 The 
examined populations consisted predominantly of middle-aged adults, thus raising the question 
as to whether the recommended cut points and risk estimates may be expanded to the elderly. 
Only limited data are available regarding the CRP distributions in the elderly and the prognostic 
utility of CRP values in CHD participants. Compared with middle-aged adults in other reports 29 
30 31  32 33 34 35, the US elderly (? 65 yrs) appeared to have higher CRP level,' 36 37 and CRP levels 
were higher among subjects with than without subclinical CVD, 37 but not to determine whether 
CRP distributions varied among groups defined by age, sex, race, and prevalence of CHD. The 
Women's Health Study (WHS) observed a slight change in CRP concentration with age: median 
CRP concentrations for individuals 45-54, 55-64, 65-74, and 275 years of age were 1.3 1, 1.89, 
1.99, and 1.52 mgll, respectively, 33 whereas no data on prevalence of high-risk levels of CRP in 
older Americans, and determining whether these prevalence varied by age, sex, race, and 
prevalence of CHD. 
3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, commonly referred 
to as statins, have anti-inflammatory (/plaque-stabilization) properties and can lower the elevated 
CRP levels, in addition to their lipid-lowering roles. l 9  Experimental data indicated that statins 
reduce macrophage content within atherosclerotic plaques,38 39 40 " " suppress the expression of 
metalloproteinases involved in the fibrous cap diss0lution,4~ 44 45 and inhibit the expression of 
adhesion molecules critical for monocyte attachment and adhesion to the endothelial 
(Figure 2) Recent trials suggested interventions to lower CRP values and have linked decreased 
levels of CRP to a reduction in secondary cardiovascular  event^,^ 47 48 in particular, effective in 
reducing stroke risk.49 Although the elderly have the higher prevalence and a much higher risk of 
cardiovascular morbidity and mortality than middle-aged persons, few population-based data 
currently exist regarding the distribution of CRP among old Americans with initial statins use. 
For example, recent studies of CRP and cardiovascular disease mainly consisted of the middle- 
aged adults. 6 7 8 49 50 51 52 53 54 55 56 57 58 59 60 61 H ~ ~ ~ ~ ~ ~ ,  only limited prospective 
epidemiological studies of CHD or stroke and markers of inflammation in the elderly have been 
performed in one study to date. 37 47 52 62 63 In the elderly, elevated CRP was associated with 
major coronary events in several studies, 32 37 64 even after extensive adjustment for CVD risk 
factors and measures of subclinical atherosclerosis, 37 and strong associated with ischemic stroke 
in C H S . ~ ~  But the strength of these relationships has been modest in some studies.65 66 The 
magnitude of relative risk in elevated CRP is attenuated after multivariable adjustment, including 
loss of statistical significance.67 
Several studies suggested that the association of CRP and stroke might be stronger in older men 
compared to olded women without preexisting stroke or chronic atrial fibrillation from the 
C H S . ~ ~  In the same study of elderly subjects, no gender and race difference in the risks of CHD 
with CRP existed in the elderly without prior vascular diseases,47 but not providing the 
supported data. Similarly, although the risks of vascular disease with CRP were greater for older 
women vs. men with evidence of subclinical cardiovascular disease in CHS and in the Rural 
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Health Promotion Project, interactions with sex were not statistically significant. '' In another 
study of healthy middle-aged women, the future risk of either MI or stroke for women in the 
Women's Health Study (WHS) 52 with elevated CRP was higher than for men. In the Physicians 
Health Study (PHS),~ possible because these differences reflect chance or effect modification by 
sex, and based on comparisons of these risks across different studies with heterogeneous study 
populations. Xia, I am not sure what you mean in the info on WHS and PHs. Perhaps break into 
a couple of sentences. Adjustment for prior vascular diseases and stroke, and effect modification 
by sex or race, and direct comparisons of these risks between men and women within the same 
sample, might provide more complete adjustment for potential confounding, yielding new 
information on the sex- or race-specific effects of CRP with CHD or stroke. 
To address the issue of the estimates of baseline CRP levels and risk of subsequent CHD or 
stroke events, we examined the distribution of CRP concentrations in members of the 
Cardiovascular Health Study original cohort at baseline, and related the baseline plasma 
concentrations of CRP to incident first coronary heart disease or ischemic stroke in these subjects 
free of vascular disease or stroke during a 8-year follow-up time. 
The specific purposes were: (1) to describe the distribution of CRP in the elderly, and to 
determine whether the CRP distributions vary by age among the elderly, gender, race, prevalent 
CHD, commonly used cardiovascular drugs, and statin uses (2) to estimate the increase in risk 
for coronary heart disease or ischemic stroke among the US elderly due to elevated CRP levels 
(>3mg/l) (3) to determine whether there exists a sex- or race-specific effects of CRP on CHD or 
stroke. 
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METHODS 
Study design and data 
The CHS is a prospective, population-based, longitudinal, and observational study of risk factor 
for cardiovascular disease in 5888 adult 265 years of age. Of these, 2955 women and 2246 men 
were enrolled at 4 centers in either 1989 to 1990 or 1992 to 1993. The first cohort consisted of 
5201 primarily white participants and the second consisted of 687 blacks. Invited participants 
were a random sample of Health Care Financing Administration eligibility lists and their 
household members in four counties6' : Forsyth County, North Carolina; Washington County, 
Maryland; Sacramento County, California; and Allegheny County, Pennsylvania. 
Exclusion criteria included institutionalization, active cancer treatment, or expectation of moving 
from the area with 2 years. All the participants provided informed consent, and the institutional 
review boards approved the CHS study. 
Study Subjects 
A total of 5713 adults had a value for CRP concentration. This cohort was examined for the 
distribution of CRP across various age, gender, co-morbid, and medication use groups. To 
examine the relation of CRP with incident CVD, 1854 participants were excluded because of the 
presence of confirmed prebaseline cardiovascular heart disease (n=1540, myocardial infarction, 
angina, congestive heart failure, stroke, transient ischemic attack, claudication, coronary artery 
bypass surgery, angioplasty, and carotid endarterectomy), and 3 14 women using oral 
postmenopausal hormones which have been reported to result in an elevation in CRP levels with 
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uncertain clinical consequence .51 69 Thus, 3859 participants were considered for analyzing -the 
association of CRP and incident CHD or ischemic stroke. 
CRP Measurements 
In 1997, CRP was measured in all stored baseline plasma samples by use of an enzyme-linked 
immunosorbent assay developed at the CHS central blood laboratory.27 70 It is a colorimetric 
competitive imm~lnoassay that uses purified protein and polyclonal anti-CRP antibodies, with an 
interassay coefficient of variation of 6.25%. 
Baseline Defin itions 
Primary analysis of CHD or ischemic stroke events categorized CRP as low (<1 mg/L), 
intermediate (1 to 3 mg/L), or elevated (>3 mgIL) to address the utility of recent guidelines. 
Diabetes mellitus and impaired fasting glucose was defined using the American Diabetes 
Association criteria. Hypertension was defined as blood pressure 2140190 mm Hg or self- 
reported hypertension with the use of antihypertensive drugs. Hyperlipidemia was defined as 
cholesterol 26.22 mmol/L (240 mgldl), LDL cholesterol 24.14 mmol/L (160 mgldl), or use of 
medications for hyperlipidemia. Cigarette use was categorized as never, former, or current and 
by number of packyears. Total alcohol per week among drinkers was defined as the number of 
alcoholic beverages (beer, wine, or liquor) consumed per week. 
Definition of CHD and Ischemic Stroke Events 
Subjects were examined annually, and followed up every 6 months by alternating field center 
visits and telephone calls between enrollment and June 30, 1997. Vascular outcomes were 
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ascertained by self-report and review of discharge codes for all hospitalizations. CHD was 
defined as myocardial infarction (MI) or coronary death. For suspected coronary events, medical 
records were abstracted and then reviewed and classified by a committee using standardized 
c rite ria.^' 72 CHD death was defined as the absence of nonatherosclerotic cause of death and 1 or 
both of the following: chest pain within 72 hours of death or history of chronic ischemic heart 
disease in the absence of valvular heart disease or nonischemic cardiomyopathy. 
Incident stroke was ascertained by self-report or from the Health Care Financing Administration 
hospitalized patient database of International Classification of Diseases, 9th Revision (ICD-9) 
codes.73 For confirmation and classification of stroke type, hospital records, including cranial 
computed tomography and cerebral magnetic resonance images, were reviewed by a committee 
that included neurologists and a neuroradiologist. Only ischemic cerebral infarction was included 
as stroke in this analysis. Those participants who suffered primarily from hemorrhagic stroke 
were not included in this analysis. 
Statistical Analysis 
SAS version 9.10 software was used for analysis with the CHS database collected by June 30, 
1997. Student's t test was used to estimate the range of CRP levels. Independent t test and the 
analysis of variance (ANOVA) test was used to evaluate the differences in CRP means by age, 
gender, race, or commonly used cardiovascular drugs. Because the distribution of CRP levels 
was skewed to the right, the distribution was log-normalized, and the transformed values were 
used for analyses. For ease of interpretation, median and standard errors of untransformed values 
were reported. The xZ statistic was used to test .the proportions of the CHS cohorts for the 3 
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categories of CRP levels, and their differences in age, gender, race, or commonly used 
cardiovascular drugs. The Cochran-Armitage Trend Test was computed for the association 
between categorical CV variables and CRP risk categories. Multiple linear regression analyses 
were used to estimate the correlation between continuous CV risk factors and CRP, and to 
calculate the least-square-adjusted means of CRP levels for subjects with and without statin uses. 
Log-rank test was used to test differences in probability of survival for CHD or ischemic stroke 
by strata of CRP risk level, overall, and by gender and race. Cox Proportional Hazards analyses 
(forward and stepwise selections) were performed to compute hazard ratios as estimates of 
relative risk of CHD with increasing category of CRP with adjustment for age, sex, and race in 
all participants and in subgroups defined by sex or race. Censoring occurred at death, last follow- 
up, or June 30, 1997, whichever occurred first. Differences in findings by sex and race were 
evaluated formally by adding interaction terms of each for these factors with CRP to the model. 
All P values were two-tailed, and values of less than 0.05 were considered to indicate statistical 
significance. All confidence intervals were calculated at the 95 percent level. 
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RESULTS 
The baseline characteristics by three CRP categories among the 571 3 elderly are shown in Table 
1. Compared with levels considered to be normal, subjects with elevated CRP had a marked 
higher prevalence of diabetes, hypertension, smoking, statins uses, and more common with less 
education. People with elevated CRP had a higher mean BMI, triglyceride and fibrinogen level, 
lower mean HDL level, and consumed alcohol less often. Women and blacks were more likely to 
have higher CRP concentration. In this restricted population cohort of participants > 65 years, 
there was no increase of CRP levels with increasing age. 
The distribution of CRP concentrations by gender, age, race, and commonly used CV drugs in 
5713 subjects (> 65 years of age) is presented Tables 2. CRP concentration ranged from 0.1 to 
119.3 mg/l, a wide range due to skewness of the biomarker. The geometric mean (SE) 
concentration was 1.97 (0.01) mg/l and the median was 1.92 mgll. Because the distribution of 
CRP is highly skewed to the right, the distribution was log-normalized, and the transformed 
values were used for analyses (Table 3). The unadjusted geometric mean of CRP concentrations 
was higher in women than in men (2.05 vs. 1.88 mgll, P = 0.00 19), in blacks than in whites (2.56 
vs. 1.82 mgll, P <0.0001). The unadjusted geometric mean of CRP was 2.23 and 1.62 mg/l for 
participants with and without commonly used cardiovascular drugs. There was no significant 
difference in CRP means across age groups (P = 0.1752). As Table 4 shows, subjects were 
unequally distributed across CRP risk categories, 26% (n=1472) with CRP < l  .O mg/l, 44% 
(n=2525) with levels of 1 to 3 mg/l, and 30% (n=1716) with elevated values >3 mg/l. The 
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prevalence of elevated CRP values was 32% in women and 27% in men, 42% in blacks and 28% 
in whites, 35% and 22% in subjects with and without CV drug uses, respectively. 
We further examined the distribution of CRP concentrations separately among 1104 subjects 
with prevalent CHD and 3859 subjects free of CVD at the baseline examination. Overall, CHD 
participants had higher CRP levels (median, 2.32 mgll) with the narrower range than those at risk 
of CVD (median, 1.75 mgll) (Tables 5 and 6) .  In unadjusted analyses, the difference in CRP 
levels between black and white (69%) and between women and men (33%) were greater for 
CHD participants than for subjects free of CVD, but the similar pattern of these differences to 
observations for the whole cohorts (Tables 7 and 8). The CRP distribution by commonly used 
CV drugs was not different between these 2 groups. As summarized in Tables 9 and 10, CHD 
participants (36%) at baseline have the higher prevalence of elevated CRP values than those free 
of CVD (26%). Compared with those in normal levels of CRP, more prevalent CHD participants 
were in the higher-risk range (CRP >3mg/l), with 3 times for blacks, twice for women, nearly 
double for CV drug users. Among these CHD participants, the prevalence of elevated CRP 
values was 40% in women and 34% in men, 47% in blacks and 34% in whites, 38% and 25% in 
subjects with and without CV drug uses, respectively. In contrast, less men, whites, and subjects 
without CV drug uses were in the CRP levels more compared with less than 3 mgll. 
Specifically, statins, a key CV drug clinically indicated in current treatment guidelines, may 
independently lower the elevated CRP levels in order to reduce the risk of CHD and stroke. 
Here, we examined the CRP distribution by statin use, separately in the whole cohort and among 
subjects with prevalent CHD (Tables 11 and 12). In unadjusted analyses, the crude CRP 
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concentration was higher among stain users than nonstatin users (geometric mean, 0.82 vs. 0.68 
mgll). After adjusting for age, gender and race, the least-squares-adjusted geometric mean for 
statin users was 0.76 mgll, and that for nonstatin users was 0.71 mgll. There was no significant 
difference in CRP concentrations among subjects with and without initial statin uses (P = 
0.3 155). Among baseline CHD participants, 37% of statin users and 36% nonstain users were at 
high-risk levels of CRP. Compared with statin users, nonstatin users with CHD were more 
common in elevated CRP levels than normal levels (36% vs. 21%) 
To determine the correlation between traditional CV risk factors and CRP, we performed the test 
for trend and multiple linear regression analysis with log-transformed CRP concentration as the 
dependent variable. As summarized in Tables 13 and 14, increasing CRP levels were correlated 
with a number of CV risk factors in unadjusted analyses, including education status, diabetes, 
hypertension, smoking, BMI, and fibrinogen. Importantly, female gender and black race were 
both associated with higher CRP levels. The correlation between CRP and diabetes was stronger 
than the correlation between CRP and other CV risk factors. 
Different CRP concentrations may have different impact on clinical outcomes. First, we 
examined the risk association of CRP to CHD or ischemic among subjects without preexisting 
vascular disease or stroke. Then, we determine the sex-specific and race-specific effects on these 
risk relationships. 
Among the 3859 elderly without prior vascular disease or stroke (Table 15), gender, race, and 
diabetic status were associated all with incident CHD and ischemic stroke. Isolated systolic 
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hypertension, pack-years smoke, and alcohol drinking were also associated with incident CHD. 
Hypertension was associated with incident ischemic stroke. Because these characteristics were 
associated with both incident CVD and CRP, we controlled for them in the analysis of the 
relationship of incident CHD or ischemic stroke to CRP. 
As summarized in Tables 16 and 17, during a follow-up time of 8 years, 270 first MI or CHD 
deaths occurred, with the incidence rate of 10.7 per 1000 person-years and the 8-year cumulative 
incidence of 7% for total subjects. The incidence increased with each higher CRP category (log- 
rank test for differences, P =0.0029). For men and whites, the incidence rates of CHD increased 
with each higher CRP category (log-rank test, P =0.0006 and P =0.0015, respectively). The CHD 
incidence for men was significantly higher than women (log-rank test, P < 0.0001), with the 
crude incidence rates of 15.5 and 7.5 per 1000 person-years in men and in women, respectively. 
However, there appeared no racial difference in the incidence of CHD (log-rank test, P = 
0.1 163). 
Table 16 shows the incidence rates and relative risks of CHD by baseline CRP categories among 
3859 participants (2 65 yrs), CHS 1989-1997. The crude relative risks of CHD were slightly 
increased for intermediate CRP, and there was a 62% increased risk for participants with 
elevated CRP >3 mgll compared to those with CRP<l mgll. Adjustment for age, sex, and race 
yielded little attenuation and rather demonstrated a more pronounced association with a nearly 
doubled risk of CHD for CRP >3 mgll. Further adjustment for other traditional cardiovascular 
risk factors attenuated these relative risks, but there was still a 47% increased risk in CHD 
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comparing CRP >3 mgll to < 1 mgll, a finding that was statistically significant (95%CI, 1.05- 
2.06). 
When CRP was considered as a continuous variables with adjustment for traditional 
cardiovascular risk factors, the relative risk associated with a 1 -1n-unit-higher baseline CRP was 
1.19 (95% CI, 1.04 to 1.37). The adjusted population-attributable risk percent (PAR %) for 
elevated CRP was 1 1.2%. Should a table be referenced? 
To determine if the gender or race differences in the associations of CHD with CRP exist, we 
estimate these risk association of CHD with CRP separately in men and women, whites and 
blacks (Table 17). 
In sex-stratified analyses, the crude relative risk of CHD in elevated compared with normal 
levels of CRP was 2.09 (95%CI, 1.37-3.20) in men and 1.30 (95%CI, 0.80-2.1 1) in women. 
Further adjustment for traditional cardiovascular risk factors reduced these relative risks to 1.78 
in men (95%CI, 1.14-2.80) and to 1.1 1 in women (95%CI, 0.66-1.86). The approximate 50% 
increase in risk for each gender group is similar to what was demonstrated overall. However, it 
was not statistically significant most likely due to reduced statistical power. We further explored 
whether gender modified the association of CRP with CHD risk and did not find effect 
modification (P for interaction, 0.1398). 
In race-stratified analyses, the crude relative risk of CHD in elevated compared with normal 
levels of CRP was 1.72 (95%CI, 1.23-2.40) in whites and 0.99 (95%CI, 0.34-2.98) in blacks. 
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Further adjustment for traditional cardiovascular risk factors reduced the relative risks to 1.43 in 
whites (95%CI, 1.01-2.04), which was not statistically significant, but actually increased the 
relative risk to 1.18 in blacks (95%CI, 0.35 - 3.94), which also was not statistically significant. 
We found no effect modification of race on the CRP-CHD risk association (P for interaction, 
0.7086). 
As summarized in Tables 18 and 19, during a follow-up time of 8 years, 245 first ischemic 
strokes occurred, with the incidence rate of 9.7 per 1000 person-years and the 8-year cumulative 
incidence of 6% for total subjects. The incidence increased with each higher CRP category (log- 
rank test, P =0.0008). The incidence of ischemic stroke across CRP categories for men was 
statistically significant (log rank p-value 0.0016) and CRP was more strongly related to incident 
stroke among men than women (log-rank test for women, P 0.0806; interaction p-value < 
0.0001). The number of ischemic stroke events in Blacks was extremely small (32 vs. 212 in 
Whites), resulting in low statistical power to detect relationships among Blacks and to detect a 
possible race interaction. 
Table 18 showed the incidence rates and relative risks of ischemic stroke by baseline CRP 
categories among 3859 participants (2 65 yrs), CHS 1989-1997. The crude relative risks of 
ischemic stroke were slightly increased for intermediate CRP, and there was a 79% increased 
risk for elevated CRP >3 mgll. Adjustment for age, sex, and race yielded little attenuation. 
Further adjustment for other traditional cardiovascular risk factors attenuated these relative risks, 
but the association of elevated levels of CRP with ischemic stroke persisted. There was a 58% 
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increased risk for participants with CRP >3 mgll (95%CI, 1.10-2.29) compared to those 
participants with CRP < 1 mgll. 
When CRP was considered as a continuous variables, with adjustment for traditional 
cardiovascular risk factors, the relative risk associated with a 1 -1n-unit-higher baseline CRP was 
1.15 (95% CI, 1 .O1 to 1.3 1). The adjusted population-attributable risk percent (PAR %) for 
elevated CRP was 13.3%. 
To determine if the gender or race differences in the associations of ischemic stroke with CRP 
exist, we estimate these risk association of ischemic stroke with CRP separately in men and 
women, whites and blacks (Table 19). 
In sex-stratified analyses, the crude relative risk of ischemic stroke in elevated compared with 
normal levels of CRP was 2.36 (95%CI, 1.37- 4.06) in men and 1.48 (95%CI, 0.95-2.31) in 
women. Further adjustment for traditional cardiovascular risk factors reduced these relative risks 
to 2.1 1 in men (95%CI, 1.20 -3.72) and to 1.54 in women (95%CI, 0.99 - 2.42), associations that 
were statistically or nearly statistically significant. There was no effect modification of gender on 
the CRP-stroke association (P for interaction, 0.1721). 
In race-stratified analyses, the crude relative risk of ischemic stroke in elevated compared with 
normal levels of CRP was 1.83 (95%CI, 1.27-2.65) in whites and 1.30 (95%CI, 0.50-3.39) in 
blacks. Further adjustment for traditional cardiovascular risk factors reduced these relative risks 
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to 1.65 in whites (95%CI, 1.1 1- 2.45) and to 1.33 in black (95%CI, 0.47- 3.77). As stated above, 
the number of ischemic strokes in Blacks was low. 
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DISCUSSION 
This population-based study describes the CRP distribution, based on results obtained with a 
high-sensitivity CRP assay, in the US elderly. Older Americans have higher CRP concentrations 
than middle-aged ones, but no increase with increasing age in this restricted cohort (all 
participants > 65 yearso. CHD participants have higher CRP levels than healthy population. 
Women, blacks, and individuals with prevalent CHD, and CV drug users have higher prevalence 
of high-risk levels of CRP. Similarly, statins users have higher prevalence of elevated CRP 
values and in general mean CRP levels were higher in statin users vs. nonusers, though only 126 
individuals were users. As in middle-aged adults,32 33 34 the distribution of the CRP level in the 
elderly is skewed toward the higher values, with most populations showing >95% of subjects 
with CRP values of <10 mgll. These data provide the reference on CRP risk thresholds in the 
elderly, and have a substantial clinical implication because it clearly demonstrates that a single 
set of cutpoints for risk assessment of future coronary and stroke events can be used for the 
elderly. 
In this prospective and longitudinal study, we demonstrate that elevated CRP levels were 
independently associated with incident CHD or ischemic stroke in the elderly without preexisting 
vascular diseases or stroke. The current study extends these findings in various sex and race 
groups, indicating that no sex or race difference in the risk relationship of CHD or ischemic 
stroke to CRP. Our findings will help define the most effective and efficient use of inflammatory 
marker CRP in the prediction of CHD and stroke. The addition of elevated CRP levels to the risk 
factor profile of the elderly may significantly increase the predictability of incident CHD or 
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ischemic stroke. Thus, the use of CRP values may aid in identifying a potentially large number 
of men and women who are at risk for CVD events, which, in turn, lead to the development for 
new preventive strategies for primary CHD and stroke prevention in those individuals identified 
as being at risk for developing CVD. Is this where you want to add the PAR% in terms of 
clinical relevance? 
Distribution of CRP concentrations 
Previous studies evaluating the distribution of CRP were mainly limited to middle-aged adults. 
The median of CRP concentrations was 1.52 mgll for healthy US women and 1.50 mgll for men 
in meta-analyses,33 the median of 1.6 mgll for US men in NHANES. 32 For healthy US adults, 
there was only a slight change in CRP level with age: median CRP concentrations for individuals 
45-54, 55-64, 65-74, and 175 years of age were 1.3 1, 1.89, 1.99, and 1.52 mgll, respectively. 33 
In our data, the median CRP concentration was higher among all participants, with 30% subjects 
of more than 3mgl1, close to reports from Cushman et a1 37 using same dataset, indicating that the 
median CRP level in subjects without prior vascular was 1.76 mgll, with 26% of more than 
3mgll. CHD participants have higher CRP concentrations than those free of CVD. Consistent 
with this finding, Tracy et a1 36 showed that mean CRP level of female CVD case subjects or 
control subjects was 3.33 vs. 1.90 mgll in the CHS cohorts with subclinical CVD; geometric 
mean of baseline CRP was 1.98 mgll with subclinical CVD and 1.64 mgll without subclinical 
CVD in the CHS cohorts. 37 In the same dataset, baseline median CRP level were 2.07 and 1.87 
mgll in the groups with and without incident ischemic stroke.63 Our finding provides support for 
the pathophysiology that the inflammatory processes play an important role in the development 
of atheroscler~sis. '~ l 9  Moreover, old people are more likely to show signs of relatively poor 
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health (such CV risk factor as. diabetes, hypertension, and smoking) than middle-aged adults, 
and higher CRP levels may reflect this risk factor burden. 
The CRP concentrations varied by sex, race, and by commonly used cardiovascular~drugs, but no 
difference by age, among older Americans regardless of the presence of confirmed CHD. 
Women have higher CRP levels -than men, blacks have higher CRP than whites, consistent with 
observations in other studies including middle-aged adults. 31 32 34 35 In Dallas Heart the 
median CRP level was almost twice as high in women compared with men, 30% higher in black 
subjects than in white subjects. Our data showed that CRP levels appeared to be higher among 
subjects with than without CV drug uses. However, our comparisons were performed in the 
unadjusted analyses. For example, the higher CRP levels in women than in men were attributed 
to estrogen use. Hormone replacement therapy, whether it is with estrogen alone or in 
combination with progestin, is known to significantly increase CRP concentration. 69 75 
therefore is imperative that future studies examine the distribution of CRP concentrations after 
adjustment in the elderly. As we analyzed the association between CRP and CHD and ischemic 
stroke, we excluded women receiving hormone replacement therapy. On the other hand, some of 
these demographic differences in CRP concentrations may be attributable to differences in health 
status (such as presence of disease) and presence of known correlates of CRP concentration or 
genetic factors. These data therefore suggest that either unmeasured or genetic factors could 
account for these differences in CRP concentrations. Heritability studies further suggest that 35% 
to 40% of the variance in CRP levels is genetically determined.74 Although self-designation of 
gender or race cannot be assumed to be a surrogate for genetic inheritance, self-designation has 
yielded important data regarding differences in cardiovascular morbidity and mortality in .the 
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United States. Thus, our findings supported the hypothesis that differences in CRP levels among 
different sex or race groups may help explain part of the residual disparity in coronary heart 
disease morbidity and mortality associated with sex and race. 
Although subjects with prebaseline confirmed CHD have higher CRP levels than those free of 
CVD at baseline, the adjusted geometric mean of CRP concentrations are similar among subjects 
with and without statin uses. Our data provide support for the hypothesis that statin therapy may 
results in a greater clinical benefit when CRP levels are elevated,48 76 and to lower CRP levels in 
a manner that is largely independent of LDL cholesterol levels. 48 77 78 79 Unfortunately, we do 
not have adequate statin intake data in the present study to address this issue. Moreover, statin 
users most likely have clinically manifest disease, also associated with higher levels of CRP and 
therefore we cannot rule out confounding by indication. Future study is needed to examine the 
change of CRP concentrations before and after initially statin therapy, and to determine whether 
reductions in CRP levels from pharmacological interventions are associated with reductions in 
CVD risk. The utility of CRP as a target of therapy remains to be proved, and these ongoing 
efforts will likely provide us with guidance. 
Along with other reports,23 76 80 81 82 83 84 we demonstrated that CRP was correlated to diabetes, 
hypertension, smoking, education status, BMI, LDL, triglyceride, fibrinogen, and alcohol uses. 
Importantly, female gender and black race were both associated with higher CRP levels. 
Elevated levels of CRP are not disease specific but are sensitive markers produced in response to 
tissue injury, infectious agents, immunologic stimuli, and inflammation. Our findings will help 
identify the factors affecting CRP levels. 
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CRP-CHD and CRP-Ischemic stroke associations 
In this prospective CHS study, we confirmed prior observations ' 37 63 that elevated CRP is 
associated with future CHD or ischemic stroke and extended prior findings to determine whether 
there were the sex and race differences in these risk associations. 
Our 8-year prospective study in the elderly free of CVD demonstrated a strong relationship 
between elevated CRP levels and incidence of first CHD or ischemic stroke, and a graded 
increase in the incidence of first CHD or ischemic stroke with increased levels of CRP. Elevated 
CRP levels were associated with a 1.47-fold increased risk of CHD and 1.58-fold increased risk 
of ischemic stroke, with adjustment for other vascular risk factors, as reported by other studies.' 
37 63 The similar study analyses using the same dataset showed that the elderly with elevated 
CRP levels had 1.48-fold increase in risk of C H D , ~ ~  and 1.60-fold increase in risk of ischemic 
stroke.63 Previous data on plasma CRP levels and CHD or ischemic stroke have suggested that 
this plasma marker is an independent predictor of the risk of future CHD or stroke among 
healthy middle-age  adult^.^ 52 Participants with the highest baseline CRP values had twice the 
risk of ischemic stroke among men, a 5-fold increase in risk of any vascular event among 
women and a 7-fold increase in risk of the combined outcome of myocardial infarction or 
stroke.s2 Our findings of an independent association of CRP in the risk of CHD or ischemic 
stroke suggest a hypothesis of an additional pathophysiological role for CRP to that of 
measurable atherosclerosis in relation to CHD or stroke. Overall, these data support the view that 
the inflammation marker CRP predicts an increased risk of atherothrombotic events in otherwise 
healthy individuals. In addition, inflammation not only appears to be a response to the underlying 
atherosclerotic disease process but also may be an integral part of it. 18 
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The relative risk of CHD or ischemic stroke for elevated CRP observed here was smaller than in 
most studies of middle-aged subjects. However, event rates of CHD and ischemic stroke were 
high in this age group, so the attributable risk percents for elevated CRP was high at 11% and 
13%, respectively, even given a modest relative risk.85 Thus, a much higher percentage of 
subjects with elevated CRP subsequently had events in this study compared with studies of 
younger subjects.86 87 If elevated CRP represents a causal risk factor as suggested by several 
experimental studies, 88 our estimate of attributable risk indicates a hypothesis that correction of 
elevated CRP could eliminate up to 1 1% of incident CHD and 13% of incident ischemic stroke 
in this age group. 
Recent reports 37 63 indicated that there were no significant differences in the risk of CHD or 
ischemic stroke to CRP by sex or race, but gender, race, and CRP interactions were not tested. 
Here, our data indicated no significant sex-CRP and race-CRP interactions in gender- or race- 
stratified analyses for theses relationship. We confirmed no effect modification by sex and race 
in the risk of CHD or ischemic stroke to CRP. 
Strengths of this study include the prospectively collected data from a large sample of older, 
community-based individuals, and long-term event follow-up. Several new findings were 
observed on the basis of unique aspects of the study. First, we examined the distribution of CRP 
concentrations in the elderly, including prevalent CHD participants and subjects free of CVD. 
Second, we described the CRP distribution by initial statin uses. Third, we confirmed an 
association of elevated CRP with the incidence of first CHD or ischemic stroke in the same older 
age group. Fourth, further stratified analyses by gender and race were performed in the 
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association between CRP and CHD or ischemic stroke. Fifth, because CRP was measured in the 
whole cohort, incidence rates of CHD by baseline CRP were calculated, and sex- and race- strata 
analyses were performed. Additionally, to preserve the generalizability of our findings, we did 
not exclude participants with various conditions in examining the CRP distributions. Excluding 
the participants with cardiovascular disease, diabetes mellitus, and a myriad of other conditions 
would have led to additional sizeable exclusions, thus calling into question the generalizability of 
our findings. 
The limitations include such points as: (1) The elderly who were willing to enroll in the study 
may not represent the general older population, so these findings can not be generalized to the 
US elderly; (2) the CHS cohorts consisted primarily of whites, the sample size of black subjects 
was too small, the sample size of statin users was even smaller, which reduced the ability to 
detect race-specific associations of CRP and CHD or stroke, and the CRP distribution among 
statin users and nonstatin subjects in important ways; (3) CRP was measured only once at 
baseline, which may not completely and accurately reflect the status of the study participants 
over a prolonged follow-up period. However, this source of variability could not account for the 
relationship observed in the present study, because a random misclassification of such nature 
would tend to underestimate study findings and bias the results toward the null hypothesis. So it 
has been suggested that repeated testing for confirmation be considered in those with high 
values." (4) the incidence of CHD or ischemic stroke in this healthy elderly cohort is relatively 
low. Although this lower incidence is likely due to selection and survival of a healthier cohort,89 
one would not expect these biases to affect prospective associations within the cohort in 
important ways. (5) The observational study design, even with extensive multivariate analysis, 
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cannot prove causal relationships. Competing risks may have diluted associations of CRP with 
CHD because CRP may be associated with other disease outcomes. (6) Other limitations include 
problem of uncontrolled confounding, the determination of CRP by a single measure which 
could result in imprecision or residual confounding due to measurement error. We believe this 
would bias our findings toward the null hypothesis, yielding underestimates of the actual risk 
associated with these measures. 
The prospective cohort design allows us to exclude the possibility that acute ischemia affected 
the levels of plasma CRP in the study participants. The data were obtained in an elderly cohort of 
men and women, and this may limit the applicability of the results to younger men and women. 
And, these findings should be further explored in studies with higher prevalence of carotid 
disease and stroke risk factors, including other population-based cohorts. 
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CONCLUSIONS 
In this prospective, population-based, longitudinal study, we observed that the CRP distributions 
varied by gender and race in the US elderly, with CHD participants having higher CRP levels 
than those free of CVD. CRP levels were similar among subjects with and without statin uses 
after adjusting for age, gender and race but the number of statin users was very small. We 
conclude that elevated CRP is independently related to the future occurrence of CHD and 
ischemic stroke in this elderly cohort. Therefore, CRP could be served as a risk factor for 
incident CHD or stroke. No gender or race difference in these risk associations exists. Because 
event rates are high overall in older age, further study is required to determine optimal clinical 
roles of CRP measurement, especially as related to interventions for elevated CRP, and to 
determine whether CRP risk threshold should be adjusted for older adults. 
Because about half of the population variance in CRP is attributable to lifestyle (e.g., smoking, 
diet, and excise) all of which are modifiable, Ridker et a190 suggested that we should develop 
better lifestyle to prevent CVD. In addition, because the other half is primarily inherited (e.g., 
polymorphisms in the CRP gene), future studies are imperative to identify the pharmacogentic 
issues that help us to figure out what participants to target for this inflammatory response. 
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TABLES 1 - 19 
Table 1. Baseline characteristics by baseline CRP concentration among 
5713 U.S. adults 2 65 vears of aae. CHS 1989-1997. 
" - 
Baseline CRP level (mgll) 
< 1 1-3 >3 
Variable (n=1472) (n=2525) (n=1716) 
Continuous variables 
Pack-year (among ever smokers) 
Body mass index, kg/m*2 
Total serum cholesterol, mgldl 
HDL cholesterol, mgldl 
LDL cholesterol, mgldl 
Triglyceride, mgldl 
Fibrinogen, mgldl 
Fasting Glucose, mgldl 
Total alcohol per week among drinken* 
Median CRP, mgll 
Cateaories variables, % 
Men 
Women 
White 
Black 
Age (years) 
65-66 
67-68 
69-70 
71-72 
73-74 
75-76 
77-78 
79-80 
80+ 
High school education or  less** 
Diabetes 
Hypertension 
Isolated systolic hypertension 
Current smoker 
Statin use*** 21.4 43.7 34.9 
* Total alcohol per week among drinkers: Number of alcoholic beverages (beer, wine, or  liquor) consumed per week 
** High school education or  less refers to grade 8 o r  less, some high school, or  high school graduation or  GED. 
*** Statin: 3-hydroxy-3-methylglutaryl coenzyme A (HMG COA) Reducatace inhibitor. 
**** Values for continuous variables are means. 
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Table 2: Distribution of Baseline High-sensitivity C-reactive Protein among 5,713 American Adults 2 65 
Years of Age, CHS 19893997. 
- 
Median RANGE (mqll) 
Variables N (mgll) Min 25% 75% Max 
Total 5,713 1.92 0.07 0.97 3.41 119.30 
Gender 
Female 3277 2.03 0.07 1-01 3.61 119.30 
Male 2436 1.78 0.07 0.93 3.18 107.97 
Age, years 
6566 523 2.04 0.17 1.06 3.67 66.47 
67-68 972 2.00 0.18 1.01 3.49 107.97 
69-70 931 1.90 0.07 0.99 3.48 99.71 
71 -72 752 2.02 0.09 1 .Ol 3.38 46.00 
73-74 606 1.84 0.25 0.96 3.14 119.30 
75-76 536 1.82 0.22 0.90 3.54 82.95 
77-78 445 2.06 0.10 0.98 3.69 74.02 
79-80 358 1.78 0.20 0.88 2.91 41.77 
80+ 590 1.78 0.16 0.91 3.30 75.97 
Race 
White 481 1 1.83 0.07 0.93 3.25 119.30 
Black 864 2.56 0.17 1.22 5.62 65.54 
Other 38 2.44 0.32 0.95 5.04 17.97 
Cardiovascular drug uses' 
Yes 3579 2.18 0.07 1.11 3.89 119.30 
No 2129 1.59 0.07 0.79 2.78 99.71 
* Cardiovascular drug uses including any ACE inhibitor, any beta blocker, any aspirin use >2 days in 2 weeks, 
any diuretic, any calcium channel blocker, any hypertension medicine, any vaso dilator. 
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Table 3: Distribution of the log transformation of Baseline High-sensitivity C-reactive Protein 
among the 5713 US elderly h 65Years of Age, CHS 1989--1997. 
Log (Geometric CRP1 Geometric t-test RANGE (mclll) 
Variables 
- -- 
Min - N Mean SE CRPlmaIl) p-value 25% 75% Max 
Total 5,713 0.68 0.01 1.97 -2.66 -0.03 1.23 4.78 
Gender 0.0019 
Female 3277 0.72 0.02 2.05 -2.66 0.01 1.28 4.78 
Male 2436 0.63 0.02 1.88 -2.66 -0.07 1.16 4.68 
Age, years 0.1752 
65-66 523 0.77 1.06 2.16 -1.77 0.06 1.30 4.20 
67-68 972 0.70 1.02 2.01 -1.71 0:Ol 1.25 4.68 
69-70 931 0.68 1.02 1.97 -2.66 -0.01 1.25 4.60 
71 -72 752 0.69 1.03 1.99 -2.41 0.01 1.22 3.83 
73-74 606 0.64 0.97 1.9 -1.39 -0.04 1.14 4.78 
75-76 536 0.66 1.06 1.93 -1.51 -1.11 1.26 4.42 
77-78 445 0.75 1.06 2.12 -2.30 -0.02 1.31 4.30 
79-80 358 0.58 1.04 1.79 -1.61 -0.13 1.07 3.73 
80+ 590 0.63 1.09 1.88 -1.83 -0.09 1.19 4.33 
Race c 0.0001 
White 481 1 0.63 0.01 1.82 -2.66 -0.07 1.18 4.78 
Black 864 0.95 0.04 2.56 -1.77 0.2 1.73 4.18 
Other 38 0.87 0.18 2.44 -1.14 -0.05 1.62 2.89 
Cardiovascular drug uses' c 0.0001 
Yes 3579 0.80 0.02 2.23 -2.66 0.10 1.36 4.78 
NO 2129 0.48 0.02 1.62 -2.66 -0.24 1.02 4.60 
' Cardiovascular drug uses including any ACE inhibitor, any beta blocker, any aspirin use >2 days in 2 weeks, 
any diuretic, any calcium channel blocker, any hypertension medicine, any vaso dilator. 
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Table 4: Unadiusted ~ercentaaes of 5.713 Older Adults 2 65 Years of aae in Three Categories of baseline hsCRP 
concentration, C& 1989-1997. 
- - 
Percentaqe with baseline hsCRP concentration chi-square 
Variables N < I  mqll I --3mqll >3 mgll p-value 
n YO n YO n % 
Total 
Gender 
Female 
Male 
Age, years 
65-66 
67-68 
69-70 
71 -72 
73-74 
75-76 
77-78 
79-80 
80+ 
Race 
White 
Black 
Other 
Cardiovascular drug uses* 
Yes 
No 2129 680 31.9 972 45.7 477 22.4 < 0.0001 
' Cardiovascular drug uses including any ACE inhibitor, any beta blocker, any aspirin use >2 days in 2 weeks, 
any diuretic, any calcium channel blocker, any hypertension medicine, any vaso dilator. 
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Table 5: Distribution of Baseline High-sensitivity C-reactive Protein among 1,104 prevalent 
CHD'* Patients (at entry) 2 65 Years of Age, CHS 1989--1997. 
RANGE (mqlll 
Variables N Median Min - 
---
25% 75% Max 
Total 1,104 2.32 0.19 1.17 4.01 82.95 
Gender 
Female 499 
Male 605 
Age, years 
6566 78 
6768 142 
69-70 165 
71 -72 148 
73-74 106 
75-76 129 
77-78 107 
79-80 84 
80+ 145 
Race 
White 937 
Black 161 
Other 6 
Cardiovascular drug uses* 
Yes 964 
No 140 1.69 0.21 0.90 3.00 36.97 
' Cardiovascular drug uses including any ACE inhibitor, any beta blocker, any aspirin use 22 days in 2 weeks, 
any diuretic, any calcium channel blocker, any hypertension medicine, any vaso dilator. 
" CHD: coronary heart disease. 
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Table 6: Distribution of Baseline High-sensitivity C-reactive Protein among 3,859 Subjects 
2 65 Years of Age free O~CVD", CHS 1989--1997. 
- 
RANGE (mall) 
Variables N Median Min 
-- -
25% 75% Max 
-
Total 3,859 1.75 0.07 0.88 3.11 107.97 
Gender 
Female 2247 1.85 0.07 0.96 3.24 86.36 
Male 1612 1.64 0.07 0.86 2.95 107.97 
Age, years 
65-66 376 1.82 0.20 0.99 3.15 66.47 
67-68 695 1.86 0.18 0.93 3.25 107.97 
69-70 638 1.68 0.07 0.87 3.03 99.71 
71-72 509 1.73 0.09 0.82 3.10 46.00 
73-74 433 1.76 0.28 0.89 2.93 50.06 
75-76 339 1.75 0.22 0.82 3.32 33.23 
77-78 282 1.95 0.1 0.89 3.28 54.80 
79-80 226 1.66 0.2 0.78 2.64 41.77 
80+ 361 1.59 0.16 0.83 3.03 53.14 
Race 
White 3261 1.68 0.07 0.85 2.93 107.97 
Black 573 2.42 0.17 1.14 4.87 65.54 
Other 25 2.27 0.42 1.24 4.80 17.97 
Cardiovascular drug uses* 
Yes 2101 2.02 0.10 1.00 3.49 107.97 
No 1754 1.51 0.07 0.76 2.66 99.71 
* Cardiovascular drug uses including any ACE inhibitor, any beta blocker, any aspirin use >2 days in 2 weeks, 
any diuretic, any calcium channel blocker, any hypertension medicine, any vaso dilator. 
" CVD: cardiovascular diseases includes MI, angina, congestive heart failure, stroke, 
transient ischemic attack, claudication, coronary artery bypass surgery, angioplasy, and carotid endarterectomy. 
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Table 7: Distribution of the Loa Transformation of Baseline Hiah-sensitivitv C-reactive Protein 
among 1104 prevalent CHD** Patients (at entry) 2 63 Years of ~ g e ,  CHS 1989--1997. 
Loa (Geometric CRP) Geometric t test RANGE (mqll) 
Variables - - -  N Mean SE Meanima/~) p-value Min - 25% 75% Max 
Total 1,104 0.84 0.03 2.32 -1.66 0.16 1.39 4.42 
Gender 
Female 499 0.92 0.05 2.51 
Male 605 0.78 0.04 2.18 
Age, years 
65-66 78 1.05 0.11 2.86 
67-68 142 0.79 0.09 2.20 
69-70 165 0.99 0.08 2.69 
71-72 148 0.90 0.08 2.46 
73-74 106 0.63 0.1 1.88 
75-76 129 0.71 0.1 2.03 
77-78 107 0.92 0.1 2.51 
79-80 84 0.58 0.11 1.79 
80+ 145 0.85 0.09 2.34 
Race 
White 937 0.8 0.03 2.23 
Black 161 1.07 0.08 2.92 
Other 6 0.96 0.43 2.61 
Cardiovascular drug uses* 
Yes 964 0.87 0.03 2.39 
NO 140 0.61 0.09 1.84 -1.56 -0.11 1 . 1  3.61 
Cardiovascular drug uses including any ACE inhibitor, any beta blocker, any aspirin use >2 days in 2 weeks, 
any diuretic, any calcium channel blocker, any hypertension medicine, any vaso dilator. 
" CHD: coronary heart disease. 
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Table 8: Distribution of the Log Transformation of Baseline High-sensitivity C-reactive Protein 
among 3,859 Subjects Z 65 Years of Age free of CVD*' , CHS 1989--1997. 
LOQ (Geometric CRPl Geometric t test RANGE (mall) 
Variables N Mean SE Meanrmd) P -value Min - 25% 75% Max 
- - -  
Total 3,859 0.56 0.02 1.75 -2.66 -0.13 1.33 4.68 
Gender 0.0399 
Female 2247 0.61 0.02 1.84 -2.66 -0.11 1 . I 8  4.46 
Male 1612 0.54 0.03 1.72 -2.66 -0.16 1.08 4.68 
Age, years 0.5742 
65-66 376 0.66 0.05 1.93 -1.61 -0.01 1.15 4.20 
67-68 695 0.62 0.04 1.86 -1.71 -0.07 1.18 4.68 
69-70 638 0.55 0.04 1.73 -2.66 -0.14 1.11 4.60 
71 -72 509 0.55 0.05 1.73 -2.41 -0.20 1.13 3.83 
73-74 433 0.57 0.04 1.77 -1.27 -0.12 1:08 3.91 
75-76 339 0.57 0.05 1.77 -1.51 -0.02 1.20 3.50 
77-78 282 0.64 0.06 1.90 -2.30 -0.12 1.19 4.00 
79-80 226 0.52 0.07 1.68 -1.61 -0.25 0.97 3.73 
80+ 361 0.54 0.06 1.72 -1.83 -0.19 1.11 3.97 
Race 
White 3261 0.53 0.02 1.80 <O.OOOI -2.66 -0.16 1.08 4.68 
Black 573 0.88 0.05 1.79 -1.77 0.13 1.58 4.18 
Other 25 0.86 0.22 1.60 -0.87 0.22 1.57 2.89 
Cardiovascular drug uses* 
Yes 2101 0.71 0.02 2.01 < 0.0001 -2.30 0.00 1.25 4.68 
NO 1754 0.43 0.02 1.54 -2.66 -0.27 0.98 4.60 
' Cardiovascular drug uses including any ACE inhibitor, any beta blocker, any aspirin use >2 days in 2 weeks, 
any diuretic, any calcium channel blocker, any hypertension medicine, any vaso dilator. 
** CVD: cardiovascular diseases includes MI, angina, congestive heart failure, stroke, 
transient ischemic attack, claudication, coronary artery bypass surgery, angioplasy, and carotid endarterectomy. 
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Table 9: Unadjusted percentage of 1,104 prevalent CHD" Patients (at entry) b 65 Years of age in Three Categories 
of baseline hsCRP concentration, CHS 1989-1997. 
Percentaqe with baseline hsCRP concentration chi-square 
Variables N <l m d l  1 -3mqll >3 mqll p-value 
n YO n % n % 
Total 1104 
Gender 
Male 605 
Female 499 
Age, years 
65-66 78 
67-68 142 
69-70 165 
71-72 148 
73-74 106 
75-76 129 
77-78 107 
79-80 84 
80+ 145 
Race 
White 937 
Black 161 
Other 6 
Cardiovascular drug uses' 
Yes 964 
No 140 41 29.3 64 45.7 35 25.0 0.0066 
' Cardiovascular drug uses including any ACE inhibitor, any beta blocker, any aspirin use >2 days in 2 weeks, 
any diuretic, any calcium channel blocker, any hypertension medicine, any vaso dilator. 
" CHD: coronary heart disease. 
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Table 10: Unadjusted percentage of 3,859 Subjects 2 65 Years of age free of CVD" in Three Categories 
of baseline hsCRP concentration, CHS 1989--1997. 
Percentage with baseline hsCRP concentration chi-square 
N Variables <lmdl I --3mgll >3 mqll p-value 
n % n % n % 
Total 3859 1113 28.8 1729 44.8 1017 26.4 <O.OOOl 
Gender 
Male 1612 484 30 739 45.8 389 24.1 <0.0001 
Female 2247 629 28.0 990 44.1 628 27.9 <0.0001 
Age, years 0.0579 
65-66 376 96 25.5 181 48.1 99 26.3 
6768 695 186 26.8 31 1 44.7 198 28.5 
69-70 638 180 28.2 296 46.4 162 25.4 
71 -72 509 153 30.1 222 43.6 134 26.3 
73-74 433 127 29.3 202 46.7 104 24.0 
75-76 339 102 30.1 138 40.7 99 29.2 
77-78 282 86 30.5 112 39.7 84 29.8 
79-80 226 73 32.3 108 47.8 45 19.9 
80+ 361 I10 30.5 159 44.0 92 25.5 
Race 
White 3261 988 30.3 1491 45.7 782 24.0 <O.OOOI 
Black 573 119 20.8 227 39.6 227 39.6 <0.0001 
Other 25 6 24.0 11 44.0 8 32.0 0.4677 
Cardiovascular drug uses* 
Yes 2101 522 24.9 927 44.1 652 31.0 <O.OOOl 
No 1754 590 33.6 800 45.6 364 20.8 <0.0001 
* Cardiovascular drug uses including any ACE inhibitor, any beta blocker, any aspirin use >2 days in 2 weeks, 
any diuretic, any calcium channel blocker, any hypertension medicine, any vaso dilator. 
** CVD: cardiovascular diseases includes MI, angina, congestive heart failure, stroke, 
transient ischemic attack, claudication, coronary artery bypass surgery, angioplasy, and carotid endarterectomy. 
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Table 12: Unadjusted percentages of 5713 Adults L 65 Years of age in Three Categories of baseline hsCRP concentration, 
CHS 1989--1997 
Tablell. Baseline Range of High-sensitivity C-reactive Protein among the 5713 US elderly 2 65 Years of Age, 
CHS 1989--1997. 
Percentaqe with baseline hsCRP concentration chi-square test 
N Variables < I  mqll 1 --3rn~Il >3 mqll p-value 
hsCRP. mqldl 
N Median SE 
---- 
Unadjusted 
Statin' users 126 2.25 0.42 
Non-statin users 5581 1.91 0.08 
Mean SE 
- - 
Adjusted" 
Statin users 119 4.25 0.65 
Non-statinusers 5260 4.12 0.35 
n % n % n % 
Total 5713 1472 25.8 2525 44.2 1716 30.0 < 0.0001 
Among all subjects 
Statin uses 
Yes 126 27 21.4 55 43.7 44 34.9 0.0088 
No 5581 1444 25.9 2466 44.2 1671 29.9 < 0.0001 
Among CHD patients 
Statin uses 
Yes 51 13 25.5 19 37.3 19 37.3 0.4937 
No 1053 218 20.7 453 43.0 382 36.3 < 0.0001 
' Statin: 3-hydroxy-3-methylglutaryl coenzyme A (HMG COA) Reducatace inhibitor. 
Loa (Geometric CRP) Geometric t-test 
Mean SE mean 
--
0-value 
0.1379 
0.82 0.09 2.27 
0.68 0.01 1.97 
Geometric t-test 
Mean SE mean 
- --
~-value 
0.3155 
0.90 0.11 2.46 
0.80 0.06 2.23 
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' Statin: 3-hydroxy-3-methylglutaryl coenzyme A (HMG COA) Reducatace inhibitor. 
"Adjusted for age, gender, race. 
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Table 13. Association between C-Reactive Protein Risk Categories and Demographic 
and Clinical Variables. 
Baseline CRP level (mgll) 
Total c 1 1-3 >3 P-value 
Variable (N=5713) (n=1472) (n=2525) (n=1716) for trend 
Men (%) 3277 45.2 43.8 38.8 0.0002 
Black (%) 864 11 13.5 21 C 0.0001 
High school education or less (%) 3255 51.8 55.8 63.1 < 0.0001 
Diabetes (%) 931 9 15.6 23.7 < 0.0001 
Hypertension (%) 2537 33.9 43.6 54.7 < 0.0001 
Isolated systolic hypertension (%) 1382 22.2 24.3 25.8 0.0192 
Current Smoking 692 8.5 11.5 16.1 C 0.0001 
Statin use** (%) 126 1.8 2.2 2.6 0.1608 
* High school education or less refers to grade 8 or less, some high school, or high school graduation or GED. 
** Statin: 3-hydroxy-3-methylglutaryl coenzyme A (HMG COA) Reducatace inhibitor. 
Table 14: Multiple linear Regression results for Baseline log-transformed C-reactive Protein 
among 5713 US Adults L 65 Years of Age, CHS 1989--1997. 
Correlation partial T-test 
Variables -- Coefficie~ SE 0-value 
Pack-years smoked (among ever smokers) 
Body mass index(BMI), kglcm*2 
Total cholesterol, mgldl 
HDL cholesterol, mgldl 
LDL cholesterol, mgldl 
Triglyceride, mgldl 
Fibrinogen, mgldl 
Fasting Glucose, mgldl 
Total alcohol per week among drinkers * 
Multiple R*2 0.34 
*Total alcohol per week among drinkers: Number of alcoholic beverages (beer, wine, or liquor) 
consumed per week. 
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- .  
6768 
69-70 
71 -72 
73-74 
75-76 
77-78 
79-80 
80+ 
Gender Female 
Male 
Race Black 
White 
Other 
Education Status College Education or Higher 
High School Education or less 
Diabete No 
Yes 
Isolated Systolic Hypertension NO 
Yes 
Hypertension No 
Yes 
SMOKE Normal 
Former 
Current 
Pack-yeam (among ever smokers) 
Total Cholesterol, mgll 
HDL, mgll 
LDL, mgll 
Triglyceride, mgldl 
Fibrinogen, mgldl 
Fasting Glucose, mgldl 
Total Alcohol per week' 
Table 15. Association of traditional risk factors with lncident CHD or lschernic Stroke Over 8 years among 3859 old adults, CHS 1989-1997. 
BMI", kglm*2. 3859 270 25175.6 0.98 (0.94-1.03) 1 245 25213.3 0.96 (0.92-1.00) 
* Total alcohol per week among drinkers: Number of alcoholic beverages (beer, wine, or liquor) consumed per week 
Incident CHD 
Variables Value N Events Total P-Y HR (95% CI) 
Age, years 6566 376 17 2558.8 l.O(ref) 
" BMI: body mass index 
Incident Ischemic Stroke 
Events Total P-Y HR (95% CI) 
7 2590.9 l.O(ref) 
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Table 16. Association of Baseline CRP with Incident CHD Over 8 years among 3859 old adults, CHS 1989-1997. 
Baseline CRP level (mgll) P-value 
Incident CHD C 1 1-3 >3 Total For trend 
Events 1 total number 6611113 I 1611 729 8811017 27013859 
Cumulative Incidence % 5.9 6.7 8.7 7 
Incidence Rate11000 Person-Years 8.8 10.2 14.1 10.7 0.0029 
Model 1 
Model 2 
Model 3 
Model 4 ' 
CRP= 1-3 mgll CRP >3 mgll 
P-value for Gender and CRP interaction 
0.3379 0.1398 
P-value for Race and CRP interaction 
Model 5 ' 0.9384 0.7086 
Model l i s  a crude model. 
Model 2 is adjusted for age (categoried by 65-66, 67-68, 69-70, 71-72,73-74, 75-76, 77-78, 79-80, 80+), gender, and race (white, black, others). 
Model 3 is adjusted for the same model 2 varialbe, and education status (high school education or less and college education or higher), diabetic status (normal, 
impaired glucose tolerance, and diabetes), Isolated systolic hypertension status (normal, borderline isolated sytolic hypertension, isolated systolic HTN), 
pack-years smoked, total cholesterol, and total alcohol per week. 
' Model 4 is adjusted for model 3 variables plus Gender-CRP interaction, but excluding race. 
Model 5 is adjusted for model 3 variables plus Race-CRP interaction, excluding gender. 
** Adjusted risk ratios were derived from a multiple Cox proportional hazards analysis in which each risk ratio was adjusted for all other factors listed. 
A risk ratio higher than 1 indicates that the elderly with elevated CRP have a higher risk for CHD than those with normal CRP levels. 
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Table 17. Association of Baseline CRP with Incident CHD by Gender Over 8 years among 3859 old adults, CHS 1989-1997. 
Baseline CRF 
. . 
Men 11.1 (36) 14.9 (69) 23.2 (52) 0.0006 15.5 (1 57) 10% 
Women 7.0 (30) 7.0 (47) 9.0 (36) 0.2859 7.5 ( I  13) 5% 
White 8.8 (61) 10.7 (109) 15.1 (78) 0.0015 11.3 (248) 8% 
Black 8.6 (5) 5.4 (6) 8.5 (9) 0.8580 7.3 (20) 3% 
Among Men 
Model I 
Model 2' 
Model 3 * 
Among Women 
Model 1 
Model 2' 
Model 3 ' 
Among Whites 
Model 1 
Model 2 " 
Model 3 ** 
Among Blacks 
Model I 
Model 2 " 
Model 3 " 1.0irefj 0.48 (0.13-1.84) 1.18(0.35-3.94) 
Model I is a crude model. 
* Model 2 is adjusted for age (categoried by 65-66, 67-68, 69-70, 71-72, 73-74, 75-76, 77-78, 79-80, 80+), and race. 
Model 3 is adjusted for age, race, education status (high school education or less and college education or higher), diabetic status (normal, impaired glucose 
tolerance, and diabetes), Isolated systolic hypertension status (normal, borderline isolated sytolic hypertension), 
pack-years smoked, total cholesterol, and total alcohol per week. 
** Model 2 is adjusted for age (categoried by 65-66, 67-68, 69-70, 71-72, 73-74, 75-76, 77-78, 79-80, 80+), and gender. 
" Model 3 is adjusted for age, gender, education status (high school education or less and college education or higher), diabetic status (normal, impaired glucose 
tolerance, and diabetes), Isolated systolic hypertension status (normal, borderline isolated sytolic hypertension), 
pack-years smoked, total cholesterol, and total alcohol per week. 
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Table 18. Association of Baseline CRP with lncident lschemic Stroke Over 8 years among 3859 old adults, CHS 1989-1997. 
Baseline CRP level (mgll) P-value 
Incident Ischemic Stroke < I 1-3 >3 total for trend 
Eventsltotal number 5511 I 1  3 11 011 729 8011017 24513859 
Cumulative lncidence % 
lncidence Rate 1 1000 Person-Years 
Model 1 
Model 2 
Model 3 
Model 4 
CRP= 1 3  mqll CRP >3 mqll 
P-value for Gender and CRP interaction 
Model 5 ' 0.534 0.1721 
P-value for Race and CRP interaction 
Model 6 ' 0.771 0.5486 
Model 1 is a crude model. 
Model 2 is adjusted for age (categoried by 65-66, 67-68,69-70, 71-72, 73-74, 75-76, 77-78, 79-80,80+), race, and gender. 
Model 3 is adjusted for age, gender, race, diabetic status (normal, impaired glucose tolerance, and diabetes), hypertension 
status (normal, borderline hypertension, hypertension), LDL, HDL cholesterol, fasting glucose, and BMI. 
Model 4 is adjusted for age, gender, race, diabetic status, hypertension, systolic blood pressure, total cholesterol, 
and smoking status. 
* Model 5 is adjusted for model 3 variables plus Gender-CRP interaction, but excluding race. 
Model 6 is adjusted for model 3 variables plus Race-CRP interaction, excluding gender. 
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Table 19. Association of Baseline CRP with Incident Ischemic Stroke by Gender Over 8 years among 3859 old adults, CHS 1989-1997. 
Baseline CRP level (mgll) Log-rank test Cumulative Incidence 
Incident Ischemic Stroke < 1 1-3 >3 for trend Total (EventsTTotal) 
lncidence rate 11000 Person-Years, ( n of events) 
Men 
Women 
White 
Black 
Among Men 
Model 1 
Model 2 ' 
Model 3 * 
Among Women 
Model 1 
Model 2 * 
Model 3 
Among Whites 
Model 1 
Model 2 ** 
Model 3 '* 
Among Blacks 
Model I 
Model 2 *' 
Model 3 ** I .~ i re f j  1.17 io.42-3.3oj I .33 io.47-3.773 
Model I is a crude model. 
* Model 2 is adjusted for age (categoried by 65-66, 67-68, 69-70,71-72, 73-74, 75-76, 77-78, 79-80, SO+) and race. 
Model 3 is adjusted for age, race, diabetic status (normal, impaired glucose tolerance, and diabetes), hypertension 
status (normal, borderline hypertension, hypertension), LDL, HDL cholesterol, fasting glucose, and BMI. 
" Model 2 is adjusted for age (categoried by 65-66, 67-68, 69-70, 71-72, 73-74, 75-76, 77-78, 79-80, SO+) and gender. 
Model 3 is adjusted for age, gender, diabetic status (normal, impaired glucose tolerance, and diabetes), hypertension 
status (normal, borderline hypertension, hypertension), LDL, HDL cholesterol, fasting glucose, and BMI. 
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Figure 1. The inflammatory cascade. iL indicates interleukin: 
ICAhll, intercellular adhesion molecule; and HSP, heat shock 
protein. 
Figure 2. Pleiotropic effects of statins. Cholesterol-independent vasoprotective effects 
of statins. Plasminogen activator inhibitor-I (PAI-I), tissue-plasminogen activator (t-PA), 
matrix metalloproteinases (MMPs), low-density lipoprotein cholesterol (LDL-C), high 
density lipoprotein cholesterol (HDL-C) and triglycerides (TG). 
(Ref: Endres M. Statins and stroke. J Cereb Blood Flow Metab 2005;25(9): 1093-1 10.) 
APPENDIX I - SAS SYNTAX 
libname event 'F:\CHS data\original datafile\events1 ; 
option nofmterr; 
proc format; 
value EVTYPE O='no event' 
1= 'MI '
2='angina1 
3='stroke1 
4='chf1 
5='claudication1 
6 =  ' TIA' 
7='angioplasty1 
%='coronary artery bypass surgery' 
9='other deaths' 
10='ECG MI (silent) 
ll='other CHD deaths'; 
value TTOEVENT O='UNKNOWN1 ;
value INCREC O='RECURRENT1 
l='INCIDENT1 
2='NOT ASSESSED' 
9='UNKNOWN' ; 
value FATAL O='NOT FATAL' 
1= ' FATAL' 
9='UNKNOWN' ; 
value DEFPROB O='PROBABLE1 
l='DEFINITE' 
2='NOT ASSESSED' 
9='UNKNOWN1; 
value PROCREL O='NON-PROCEDURE RELATED' 
l='PROCEDURE RELATED' 
2='NOT ASSESSED' 
9= 'UNKNOWN' ;
value STKTYPE O='HEMORRHAGIC' 
l='ISCHEMIC' 
9='MISSING'; 
value DEATH O='ALIVE1 
1='DEATH1; 
value MIBLMOD O='INCIDENT' 
l='PREVALENT1; 
value ANBLMOD O='INCIDENT' 
l='PREVALENTT; 
value CHBLMOD O='INCIDENT1 
l='PREVALENT1; 
value CLBLMOD O='INCIDENT' 
l='PREVALENT'; 
value STBLMOD O='INCIDENTT 
l='PREVALENTT; 
value TIBLMOD O='INCIDENT1 
l='PREVALENT1; 
value BPSSUR O='INCIDENT1 
1='PREVALENT1; 
value CAROTI O=IINCIDENTT 
l='PREVALENTT; 
value CORART O='INCIDENT1 
l='PREVALENT1; 
label EVTYPE = 'Event type'; 
label TTOEVENT ='event time,in days, from study entry to event'; 
label CENSTIME='censor time'; 
label INCREC = 'Incident or recurrent'; 
label FATAL = 'fatal or non-fatal'; 
label DEFPROB = 'definite or probable1; 
label PROCREL = 'procedure related to non-related procedure'; 
label STKTYPE = 'stroke type (missing if the event is not stroke) I ;  
label DEATH = 'all deathT; 
label MIBLMOD = 'MI(myocardia1 infarcti0n)baseline modified status'; 
label ANBLMOD = 'Angina baseline modified status'; 
label CHBLMOD = 'CHF(congestive heart failure) baseline modified status'; 
label CLBLMOD = 'CLAUD(C1audication)baseline modified status'; 
label STBLMOD = 'Stroke baseline modified status'; 
label TIBLMOD = 'TIA(transient ischemic attack)baseline modified status'; 
label BPSSUR = 'coronary bypass surgery'; 
label CAROTI = 'carotid endarterectomy'; 
label CORART = 'coronary artery angioplasty'; 
RUN; 
proc print data=event.ssd; 
var EVTYPE TTOEVENT CENSTIME; 
run ; 
libname chd 'F:\CHS data\chdl; 
DATA chd.al1; 
U
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proc sort data=stk.ssd; 
by IDNO TTOEVENT; 
run ; 
data stk.ssd; 
set stk. ssd; 
by IDNO TTOEVENT; 
IF FIRST.IDN0; 
run ; 
data stk.ssd;set stk-ssd; 
if STBLMOD NE 1 and EVTYPE=3 and STKTYPE=l and DEFPROB=l then ish-stroke=l; 
else ish-stroke=O; 
label ish-stroke = 'Incident ischemic stroke'; 
run ; 
libname chdstk 'F:\CHS data\eventl; 
data chdstk.evt; 
MERGE chd-ssd 
stk. ssd; 
by IDNO; 
run ; 
data chd.censtime; 
set event.ssd (KEEP= IDNO CENSTIME TTOEVENT); 
by IDNO ; 
IF FIRST.IDN0; 
run ; 
libname BL IF:\CHS data\original datafile\basebothl; 
libname base 'F:\CHS data\basel; 
data base.ssd; 
MERGE chd-censtime 
BL.ssd (KEEP = IDNO GENDOl AGE2 CRP STTN06 ANYACE ANYBETA ASPIRIN 
ANYDIUR CCBOG HTNMEDOG ANYVASO CAROTI BPSSUR CORART EXTART 
CHDBLMOD STBLMOD MIBLMOD ANBLMOD CLBLMOD TIBLMOD CHBLMOD 
ESTBLNC ESTBL RACE01 EDUC SMOKE PKYRS DIABADA HYPER FHHA 
CHOLADJ HDL44 LDLADJ BMI ALCOH FIB44 GLUADJ TRIG44 IHYPER 
ASPIRIN MAJABN AAI) ; 
label CRP = 'c-reactive protein'; 
label STTN06 = 'HMG COA Reducatace Inhibitors (statin) I ;  
label ANYACE = 'any ACE inhibitor'; 
label ANYBETA = 'any beta blocker1; 
label ASPIRIN = 'aspirin use >2 days in 2 weeks1; 
label ANYDIUR = 'any diuretic'; 
label CCBO6 = 'any calcium channel blocker1; 
label HTNMED06 = 'any hypertension medicine1; 
label ANYVASO = 'any VASO dilator1; 
run ; 
data base.ssd;set base-ssd; 
where CRP > 0; 
if AGE2=1 then AGE3=1; 
if AGE2=2 then AGE3=2; 
if AGE2=3 then AGE3=3; 
if AGE2=4 then AGE3=4; 
if AGE2=5 then AGE3=5; 
if AGE2=6 then AGE3=6; 
if AGE2=7 then AGE3=7; 
if AGE2=8 then AGE3=8; 
if AGE2=9 or AGE2=10 or AGE2 = 11 or AGE2= 12 or AGE2 = 13 then AGE3=9; 
if CRP<1 then CRP1=1; 
Else if CRP>=l and CRP<=3 then CRP1=2; 
Else if CRP>3 then CRP1=3; 
if ANYACE=l or ANYBETA=l or ASPIRIN=l or ANYDIUR=l or CCBO6=1 or HTNMED06=1 or ANYVASO=l then CVDRUG=l; 
Else if ANYACE=O and ANYBETA=O and ASPIRIN=O and ANYDIUR=O and CCBO6=O and HTNMEDOG=O and ANYVASO=O 
then CVDRUG=O; 
if ESTBLNC=l then HORMONE=l; 
else if ESTBLNC=O then HORMONE=O; 
if CRP>3 then HCRP=l; 
else if CRP<=3 then HCRP=O; 
if RACEO1=1 then RACE02=1; 
if RACEO1=2 or RACEO1=3 then RACE02=0; 
if EDUC=l then EDUCLV=l; 


.
 .
 
d
 
a
 
.
 .
 
9. 
iii 
0
 
k
 U
 
0
 
U
 
0 
a
 
a, 
Id 
0
 
0
 
a
 
a
 
a
 
r
l 
.
 .
 
a
 
a
 
a
 
a, 
.
 .
 
k
 F: 
C
 
k
 0
 
c 
a, 
z 
& tl 
z 6- 
a, 
o
 
m 
G 
4 
G 
.
 .
 
9 
c; 
a
 
H
 
rn 
.
.
 
-
 
-
 
-
0
 
.
 .
 
F
U
 
? a
 
.
.
 
0
 3 
5
A
.
5
4
 
5
s
9
r
l
 
-
 
-
 
*. 
I1 
*
-
 
I1 
*. 
I1 
I1 
I1 
Fa 
a
d
 
0
 
N
r
l
N
 
W
O
N
 
c
.IO
N
 
r
l N
 
9. 
*
-
 
I1 
*
*
 I1 
II 
II 
k
 
a, 
.
-
 
II 
II 
II 
U
 
II 
II 
U
 
II 
II 
u
 
u
 u
 
u
C
 
o
 
m
r
l
~
 
W
O
N
 
r
l N
 
U
C
O
N
 
4
r
l
r
d
 
4
d
r
d
 
p
:rlrd
 
rd 
rd 
a
 
-
 
I 
II 
II 
U
 
II 
II 
U
 
U
 U
 
U
 
II 
U
 
W
U
U
 
U
U
 
U
A
0
c
.I 
W
r
lr
d
 
W
r
lr
d
 
p: p: 
rd 
rd 
~
U
I
I
U
 
M
u
U
 
M
U
U
 
U
 
U
 
U
 
d
r
d
 2%
2 
a
 
r
l U
 
U
 
2: 
2 
P
4
rd
p
: 
W
W
 
S
rU
W
 
rn 
rlrd
 
o
r
d
w
 
0
r
d
~
 
.
.xp:nl 
-
-
 
P
IP
I 
W
W
 
*
-
d
 U U
 
X
U
 M
 
.
-5
: U
 M
 
.
-
 
M
 M
 
a
n
r
d
w
 
m
w
o
a
m
w
o
a
 
o
o
 
*
 
c 
0
4
x
6
 
a
w
*
H
a
 
Z
E
 
.rl x
 
H
 
m
 
a
 
rl 
d
 
a, 
a
 
rl 
d
 
a, 
a, a
 
m
 
u
 
m
 
m 
rn 
k
 a
 
H
 
rn 
4
 
rn 
d
 
w
 
d
 
d
 
Q
Q
 Fl 
w
 
d
 
a
 
rd 
-4
 
a
 
a
 
rd
rd
3
 
K
i
d
 
a, 
a
 
r
l
r
l
k
 
U
 
d
d
k
 
U
 

































































































